Cardiopulmonary Bypass clinical trials at UCSF
2 in progress, 0 open to eligible people
ARTEMIS: Ravulizumab to Protect Patients With CKD From CSA-AKI and MAKE
Sorry, not currently recruiting here
The primary objective of this study is to assess the efficacy of a single dose of ravulizumab IV compared with placebo in reducing the risk of the clinical consequences of AKI (MAKE) at 90 days in adult participants with CKD who undergo non-emergent cardiac surgery with CPB.
San Francisco, California and other locations
DMSO Cryopreserved Platelets in Cardiopulmonary Bypass Surgery (CRYPTICS)
Sorry, not currently recruiting here
A randomized, parallel group, active comparator-controlled trial to evaluate the non-inferiority or superiority of Cryopreserved Platelets with Liquid Stored Platelets in controlling blood loss in patients undergoing Cardiopulmonary Bypass Surgery.
San Francisco, California and other locations
Our lead scientists for Cardiopulmonary Bypass research studies include Elaine Tseng, MD, FACS.
Last updated: